Recursion Pharmaceuticals (RXRX) shares recently closed at US$3.98, with the stock showing a negative return over the past month and past 3 months, which may prompt investors to reassess its current ...

A few stanzas from the end of Chaucer’s long poem “Troilus and Criseyde,” the author interrupts his story to indulge in a bit of reception anxiety. “Go, litel book,” he bids the manuscript that’s soon ...

Abstract: Mathematics is filled with conjectures that involve infinite recursive structure, representing complex structures and underlying deep relationships. Discovering such conjectures is crucial ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

Anthony Taormina is an original member of the GameRant team, having been part of the publication for 15 years. He coordinates content for all facets of the site and manages its social media, PR, and ...

With the recursion prevention in #13631, valid recursive partials now fail. This is a simple repro: https://github.com/n1xx1/repro-hugo-infinite-recursion If the ...